An aminoindane is a phenethylamine analogue in which the side chain of amphetamine is constrained into a five-membered ring fused to the benzene core, producing a rigid bicyclic indane scaffold bearing an amine at the 2-position.[1]
Membership in the class is defined by this shared structural motif rather than by any single receptor target, and the conformational rigidity it imposes is what distinguishes aminoindanes from the open-chain phenethylamines and amphetamines they formally derive from.
The class spans the unsubstituted parent 2-aminoindane, the methylenedioxy-substituted MDAI, and the N-methylated NM-2-AI. The members differ in aromatic substitution and N-alkylation but converge on a common monoamine-releasing action shaped by the indane ring's constrained binding geometry at the serotonin, norepinephrine, and dopamine transporters.[2]
Aminoindanes were first explored as candidate anti-Parkinsonian agents and later as ring-constrained analogues of MDMA in medicinal chemistry, before appearing on European recreational markets as novel psychoactive substances in the early 2010s following synthetic cathinone bans.[2] Across the exposure range, members produce empathogenic effects — emotional warmth, openness, and mild sensory heightening — with stimulant features secondary, and at higher exposures a serotonergic physiological load that includes hyperthermia and cardiovascular stress.[3]
Pharmacology
Aminoindanes converge on a single endpoint: carrier-mediated release of monoamines from presynaptic terminals via the membrane transporters SERT, NET, and DAT, with the indane ring's constrained geometry biasing transporter engagement toward serotonin and norepinephrine over dopamine.[2][1]
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| SERT-preferential release | MDAI | Methylenedioxy substitution sharpens serotonin selectivity, driving release at SERT well above release at DAT[2] |
| NET- and DAT-leaning release | 2-aminoindane | The unsubstituted indane core interacts more broadly with NET and DAT, with weaker serotonergic engagement[2] |
| Active metabolite of an indane parent | NM-2-AI | N-methylation is removed in vivo, so the compound functions partly as a prodrug for 2-aminoindane and inherits its transporter profile[4] |
The route to the endpoint differs across members, but the endpoint itself is what defines the class pharmacologically and what governs its safety: a serotonin-over-dopamine releasing bias that produces an empathogenic rather than a euphoriant or strongly locomotor profile.[2] The reduced dopamine contribution limits the reinforcing pull characteristic of classical amphetamines, while the elevated extracellular serotonin drives both the sought subjective effects and the class-wide acute toxicology.
Where members diverge — degree of SERT selectivity, whether norepinephrine or dopamine is the secondary target, and overall potency — shapes the individual profile of each compound, but the convergent endpoint means that combination, redosing, or coadministration with other serotonergic drugs produces additive serotonergic load across the class.
Substances
The class is illustrated by three members spanning the unsubstituted parent, a ring-substituted entactogen, and an N-alkylated derivative:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| 2-Aminoindane | Unsubstituted parent | The bare indane scaffold; releases preferentially at NET and DAT with weaker serotonergic action, and partially substitutes for amphetamine in drug-discrimination work[2] |
| MDAI | 5,6-methylenedioxy substitution | Developed in the 1990s as a ring-constrained analogue of MDA/MDMA; prototypical selective serotonin releasing agent and the most pharmacologically characterised member[3] |
| NM-2-AI | N-methylated derivative | Metabolised in vivo to 2-aminoindane as the primary active metabolite; behavioural effects in rodents are entactogenic but described as atypical and less intense than classical stimulants[4] |
These members differ in substitution pattern and transporter preference, but each contributes monoamine-releasing activity dominated by serotonin and norepinephrine over dopamine, and each carries the class's serotonergic acute-risk pattern.
Subjective Effects
Across the class, the empathogenic character is the dominant phenomenological signature: elevated extracellular serotonin drives reports of emotional openness, warmth toward others, mood brightening, and reduced social anxiety, with stimulant arousal present but secondary.[2]
| Exposure | Characteristic effects |
|---|---|
| Low | Mild mood brightening, reduced social anxiety, increased sociability, and a subtle sense of emotional openness |
| Moderate–high | Pronounced empathogenic warmth, sensory heightening, mild stimulation with elevated heart rate, and modest locomotor activation |
| High | Pronounced serotonergic load with hyperthermia, tachycardia, agitation, tremor, and rising risk of serotonin toxicity[3] |
The same serotonergic drive that produces the empathogenic character also produces the thermoregulatory and cardiovascular load at the high end of the range, and the margin between sought effects and serotonin toxicity narrows whenever additional serotonergic activity is added through redosing, warm environments, physical exertion, or coadministration with other serotonergic drugs.[2]
Safety
Risk profile
The defining acute danger of the aminoindane class is serotonin toxicity (serotonin syndrome). Because every member is a serotonin-releasing agent with SERT-preferential or SERT-significant action, any situation that substantially elevates synaptic serotonin — high doses, redosing, hot environments, or combination with other serotonergic drugs — sharply raises the risk of a syndrome that presents with hyperthermia, tachycardia, agitation, tremor, clonus, and in severe cases multi-organ failure and death.[2][1]
Combining any aminoindane with SSRIs, SNRIs, MAO inhibitors, lithium, tramadol, or other serotonergic compounds is the single highest-stakes interaction pattern for the class: the aminoindane's releasing action at SERT and the coadministered drug's action on serotonin reuptake or breakdown create a convergent serotonergic excess that drives the toxicity above.[2] There is no specific antidote — naloxone does not reverse serotonergic toxicity — and management is supportive, centred on cooling, sedation, and hospital care.
Hyperthermia is a particularly well-documented class hazard. Animal toxicology of MDAI showed hyperthermia and perspiration in group-housed rats that worsened with social density, and disseminated intravascular coagulopathy with brain oedema as the direct mechanism of death at lethal exposures.[3] Deaths attributed to aminoindane use, including UK fatalities linked to MDAI in 2011–2012, have consistently shown features consistent with severe serotonin syndrome and hyperthermia.[3]
In silico toxicology profiling of the unsubstituted and N-methylated members identified elevated probabilities of cardiovascular toxicity and pulmonary involvement, together with a genotoxicity signal for NM-2-AI.[5] These are predictive signals rather than confirmed clinical findings, but they align with the cardiovascular stress mechanisms expected of monoamine-releasing agents and reinforce the case for caution in users with pre-existing cardiovascular disease. The clinical evidence base for the class as a whole is thin: most members have not been studied in humans under controlled conditions.
Tolerance & dependence
Sustained or repeated use is expected to produce tolerance to the empathogenic and mood effects, primarily through serotonergic down-regulation — SERT changes and post-synaptic 5-HT receptor desensitisation — by analogy with the better-characterised mechanisms of MDMA tolerance.[2] Whether tolerance to thermoregulatory or cardiovascular effects develops at the same rate as tolerance to subjective effects is not established, which means redosing to chase a diminishing entactogenic effect can compound physiological risk without warning.
Because aminoindanes are markedly less dopaminergic than classical stimulants, the mesolimbic reinforcement that drives compulsive redosing in dopamine-dominant compound classes is reduced, and the class tends toward psychological rather than strongly physical dependence patterns.[2]
No clinically documented withdrawal syndrome appears in the reviewed literature; the limited recreational footprint and short market presence of most members mean the long-term dependence picture is not yet characterised, and statements about dependence liability should be read as provisional.
Recovery
Where someone has been using an aminoindane regularly and wants to stop, the practical concerns are serotonergic recovery and avoiding serotonergic stacking during that window. Recovery of the serotonin system after sustained releasing-agent exposure is expected to take weeks to months by analogy with MDMA pharmacology, and coadministering other serotonergic drugs during that period carries the same elevated toxicity risk noted above.A clinician — particularly one familiar with novel psychoactive substances or stimulant-related care — can advise on supportive care, on whether existing serotonergic medications need adjustment, and on integration support for the psychological side of stopping.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]^abcSainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA (2011) Aminoindanes--the next wave of 'legal highs'? — Drug Testing and Analysis doi:10.1002/dta.318
- [2]
- [3]^abcdePalenicek T, Lhotkova E, Zidkova M, Balikova M, Kuchař M, Himl M, Miksatkova P, Cegan M, Vales K, Tylš F, Horsley RR (2016) Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats. — Progress in Neuro-Psychopharmacology & Biological Psychiatry doi:10.1016/j.pnpbp.2016.04.004
- [4]^abTirri M, Corli G, Arfe R, Marchetti B, Bilel S, Bernardi T, Boccuto F, Odoardi S, Mestria S, Strano-Rossi S, Marti M (2023) Behavioral and Pharmacokinetics Studies of N-Methyl-2-Aminoindane (NM2AI) in Mice: An Aminoindane Briefly Used in the Illicit Drug Market. — International Journal of Molecular Sciences doi:10.3390/ijms24031882
- [5]^Jurowski K, Frydrych A (2026) First toxicity profile of 2-aminoindane and N-Methyl-2-aminoindane using in silico multi-approach. — Toxicology in Vitro doi:10.1016/j.tiv.2025.106149